Deals: Page 50
-
Evotec snaps up Aptuit in further CRO consolidation
Contract research organizations are merging at a rapid pace, at a time when their services are highly sought after by pharma and biotech companies.
By Suzanne Elvidge • Aug. 1, 2017 -
$40M cancer deal gets Redx out of the red
Loxo Oncology will pick up a cancer drug from the beleaguered U.K. company, helping Redx stave off financial woes.
By Suzanne Elvidge • Aug. 1, 2017 -
LabCorp strengthens its CRO standing with $1.2B Chiltern acquisition
The deal should expand the buyer's CRO workforce to more than 11,000 employees.
By Jacob Bell • July 31, 2017 -
Alexion leaves Moderna, others behind in R&D shake-up
The rare disease drugmaker's strategic review has led it to discontinue collaborations with the high-flying mRNA biotech as well as Blueprint and Arbutus.
By Jacob Bell • July 28, 2017 -
Prescribed Reading: Pharma marked by restructuring and failures
A week of earnings announcements emphasized changes in portfolios against the backdrop of a major pipeline failure.
By Lisa LaMotta • July 28, 2017 -
J&J inks $879M vaccine deal with Bavarian Nordic
In another multimillion deal with the big pharma, the new alliance will focus on HIV and hepatitis B.
By Suzanne Elvidge • July 28, 2017 -
Tesaro lands licensing, supply agreements for Zejula
Two separate deals have Takeda handing over $100 million upfront for rights to the cancer med and STA Pharmaceutical providing the materials to make it.
By Jacob Bell • July 27, 2017 -
After MYSTIC miss, AstraZeneca taps Merck in $8.5B cancer deal
On the heels of its MYSTIC failure, the British pharma has teamed up with Merck to jointly develop and commercialize two of its oncology drugs.
By Lisa LaMotta • July 27, 2017 -
Mitsubishi Tanabe to acquire NeuroDerm for $1.1B
The Japanese pharma agreed to pay $39 per share of NeuroDerm, a 17% premium from the target's stock price at close-of-market July 21.
By Jacob Bell • July 24, 2017 -
Nektar secures $400M deal with Lilly for Phase 1 drug
Lilly liked what it saw in the immunological candidate, paying $150 million upfront to gain access to a compound Nektar discovered just over a year ago.
By Ned Pagliarulo • July 24, 2017 -
Prescribed Reading: Bolt-on deals for Sanofi
The big pharma tries to fill its pipeline, Vertex touts strong CF data and the FDA gives three approvals.
By Lisa LaMotta • July 21, 2017 -
Exelixis and Genentech hammer out new deal terms
After a year of arbitration, the companies shook hands on a revised deal.
By Suzanne Elvidge • July 21, 2017 -
Courtesy of Sanofi
Sanofi inks immunology deal to expand pipeline
A small deal with Ablynx helps bolster Sanofi's pipeline as it rounds out its portfolio.
By Lisa LaMotta • July 20, 2017 -
Sarepta, BioMarin iron out Exondys 51 patent terms
The deal exchanges upfront, milestone and royalty payments for a patent estate covering exon-skipping therapies.
By Jacob Bell • July 18, 2017 -
Genentech BD: Alzheimer's continues to be a priority
Genentech's Tom Zioncheck sat down with BioPharma Dive to talk about the big biotech's work in Alzheimer's disease.
By Lisa LaMotta • July 17, 2017 -
Valeant unloads Obagi in latest sell-off
The beleaguered company continues to sell assets in an effort to reduce debt and move the company forward.
By Lisa LaMotta • July 17, 2017 -
BDSI inks Canadian marketing deal
BioDelivery Sciences and Purdue Pharma will be dancing cheek to cheek to launch BDSI's buccal buprenorphine in Canada.
By Suzanne Elvidge • July 17, 2017 -
Prescribed Reading: Rumors, blood and history in the making
Rumors swirl about a new CEO at Teva, hemophilia drugs are getting exciting and the first CAR-T therapy could be coming.
By Lisa LaMotta • July 14, 2017 -
Sunovion sheds asthma brands to focus on COPD
The Massachusetts drugmaker recently acquired rights to three COPD treatments from Novartis and hopes to soon win approval for its own developed therapy.
By Suzanne Elvidge • July 14, 2017 -
Elizabeth Regan/BioPharma Dive
Digital health funding hits record high in first half of 2017, Rock Health finds
Seven companies snared $100 million or more in funding during the second quarter.
By Meg Bryant • July 12, 2017 -
No game changer: Sanofi picks up flu vaccine
The French pharma is adding to its lofty vaccines portfolio with a quick bolt-on acquisition.
By Lisa LaMotta • July 11, 2017 -
Stada takeover: All over again?
After last month's unsuccessful takeover attempt, Bain Capital and Cinven have secured Stada's support for a revised bid.
By Suzanne Elvidge • July 11, 2017 -
Novartis hits pause on Fovista agreement
The Swiss drugmaker is no longer obligated to develop and commercialize Ophthotech's drug, at least until data from the OPH1004 study becomes available.
By Jacob Bell • July 10, 2017 -
J&J drops stem cell partner Capricor
Janssen Biotech's decision not to exercise an option for a cardiology candidate has batted Capricor stock.
By Suzanne Elvidge • July 10, 2017 -
Prescribed Reading: I/O is the only game in town
Immuno-oncology dominates dealmaking, clinical trial data and regulatory action.
By Lisa LaMotta • July 7, 2017
Previous
